<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083525</url>
  </required_header>
  <id_info>
    <org_study_id>WX/50-005</org_study_id>
    <nct_id>NCT00083525</nct_id>
  </id_info>
  <brief_title>Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg Pharma AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, maximum tolerated dose&#xD;
      (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine&#xD;
      in patients with advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Advanced Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WX-UK1 in combination with Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of a non-hematologic malignancy&#xD;
             that is either unresponsive to currently available therapies or for which there is no&#xD;
             known effective therapy.&#xD;
&#xD;
          -  Patient willing to give informed consent, understand and comply with study&#xD;
             procedures/restrictions&#xD;
&#xD;
          -  Age&gt;=18&#xD;
&#xD;
          -  Patients must have an ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks&#xD;
&#xD;
          -  Negative serum pregnancy test for women of child-bearing potential and not nursing.&#xD;
             Fertile patients must use effective contraception during and for 30 days (women) or 4&#xD;
             months (men) after treatment with WX-UK1.&#xD;
&#xD;
          -  Measurable or non-measurable disease. Patients without clinical or radiologic evidence&#xD;
             of disease are not eligible.&#xD;
&#xD;
          -  Laboratory parameters (obtained within the screening period): WBC &gt;= 3 G/L,&#xD;
             neutrophils &gt;= 1.5 G/L, platelets &gt;= 100 G/L, Hgb &gt;= 9 g/dL), total bilirubin &lt;= 1.5 x&#xD;
             ULN, ASAT/ALAT/AP/GGT &lt;= 2.5 x ULN, serum creatinine &lt;= 2 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to the study drugs or chemically related compounds or any&#xD;
             of the excipients&#xD;
&#xD;
          -  History of or current neurological disorder, in particular an active or treated&#xD;
             seizure disorder&#xD;
&#xD;
          -  Known standard therapy for the patient's disease that is potentially curative or known&#xD;
             to extend life expectancy.&#xD;
&#xD;
          -  Carcinomatous meningitis or untreated/uncontrolled metastatic brain parenchymal&#xD;
             disease.&#xD;
&#xD;
          -  Concurrent or prior (within 4 weeks prior to start of WX-UK1 treatment for cytotoxic&#xD;
             chemotherapy, biological-, endocrine-, investigational- or radiotherapy and 6 weeks&#xD;
             for nitrosoureas, mitomycin-C)&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Significant cardiac disease (NYHA classification III or IV&#xD;
&#xD;
          -  Contraindication to an infusion volume of 1000 ml over 2 h&#xD;
&#xD;
          -  History of or current blood coagulation disorders&#xD;
&#xD;
          -  History of or current bleeding disorder (including cerebral bleeding, recurrent&#xD;
             massive nose bleeds, hematuria or unexplained bruising)&#xD;
&#xD;
          -  Diabetes mellitus, if not controlled by insulin, oral anti-diabetic agents or diet&#xD;
             alone&#xD;
&#xD;
          -  Anticoagulant or thrombolytic therapy within four weeks prior to start of treatment&#xD;
             (except heparin flush to keep a port open or coumadin 1 mg/day or ASA 100mg/d)&#xD;
&#xD;
          -  Active serious illness that renders the patient unsuitable for study entry or multiple&#xD;
             blood sampling&#xD;
&#xD;
          -  Illness or condition that might alter the absorption, distribution, metabolism and&#xD;
             elimination of WX-UK1&#xD;
&#xD;
          -  Known Hepatitis B/C or HIV infection&#xD;
&#xD;
          -  Contraindication to capecitabine intake as specified in the SPC such as DPD-deficiency&#xD;
             or concomitant intake of sorivudine or sorivudine related compounds&#xD;
&#xD;
          -  Known hemorrhagic brain metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>May 25, 2004</study_first_submitted>
  <study_first_submitted_qc>May 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2004</study_first_posted>
  <last_update_submitted>January 21, 2008</last_update_submitted>
  <last_update_submitted_qc>January 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

